Across nearly every nation on Earth, the drugs humanity relies upon to defeat bacterial infection are being consumed in ways that hasten their own obsolescence. A landmark study in The Lancet Public Health has found that 99 percent of countries overuse the very antibiotics reserved for resistant infections, while patients who most need those medicines go without them. The paradox is as old as scarcity itself: the powerful consume what the vulnerable require, and in doing so, diminish what remains for everyone. The WHO's 2030 target offers a narrow corridor toward correction, but only if govern
Global antibiotic overuse fuels superbug crisis as 99% of nations exceed 'watch' drug targets
Patients with life-threatening drug-resistant infections risk inadequate treatment due to misallocation of reserve antibiotics and global overuse patterns.
99 percent of nations overdose on the drugs that breed superbugs
Mark
Why does it matter which class of antibiotic a country uses, as long as infections are being treated?
Mimi
Because overusing the strong drugs trains bacteria to resist them. When you use a 'watch' antibiotic for a simple ear infection that amoxicillin could have handled, you're creating an evolutionary pressure. The bacteria that survive that exposure pass resistance genes to their neighbors. Do that millions of times across a country, and you've built a generation of superbugs.
Mark
So the problem is that doctors are prescribing too much of the wrong thing?
Mimi
Partly, yes. But it's also about access. A doctor in a low-income country might not have reliable supply of basic antibiotics, so they reach for what's available—often the stronger drugs. Meanwhile, a wealthy country's doctor might prescribe a 'watch' drug out of habit or caution, even though a simpler option would work.
Mark
The study says 99 percent of countries are overusing 'watch' antibiotics. That's almost universal. How does that happen?
Mimi
There's no global enforcement. The WHO set guidelines, but countries didn't have clear targets for what their own use should be. This study provides those targets for the first time. Without them, there's been no way to know if you're doing it right.
Mark
What happens to a patient in a low-income country who actually needs a reserve antibiotic?
Mimi
They might not get it. The study found that more than half of countries aren't using enough reserve drugs. So a person with a truly resistant infection—something that only the last-resort antibiotics can touch—might be denied that treatment because the drugs are being wasted on less serious cases elsewhere.
Mark
Is this fixable?
Mimi
The study suggests yes. The UN target of 70 percent access-group use by 2030 is mathematically achievable. But it requires countries to simultaneously cut unnecessary prescribing and guarantee access where it's actually needed. That's a policy problem, not a scientific one.
The Pulse
- Researchers have confirmed what many feared: the global antibiotic system is not merely strained but structurally inverted, with stronger drugs overused and weaker, safer ones underused almost everywhere at once.
- The 'watch' antibiotic category — drugs meant only for infections that resist simpler treatment — is being prescribed recklessly in 99 percent of countries, accelerating the evolution of bacteria that no existing medicine can reliably kill.
- India alone was consuming nearly double its calculated safe antibiotic threshold, with more than half that excess drawn from the very drug classes that should be held in reserve.
- A bitter inequality runs beneath the data: wealthy nations consume the specialized antibiotics that low-income countries, carrying far greater infectious disease burdens, actually need most.
- The WHO's 2030 benchmark — 70 percent of antibiotic use drawn from basic access drugs — remains mathematically achievable, but only through immediate, coordinated national policy reform that currently does not exist at scale.
Across nearly every nation on Earth, the drugs humanity relies upon to defeat bacterial infection are being consumed in ways that hasten their own obsolescence. A landmark study in The Lancet Public Health has found that 99 percent of countries overuse the very antibiotics reserved for resistant infections, while patients who most need those medicines go without them. The paradox is as old as scarcity itself: the powerful consume what the vulnerable require, and in doing so, diminish what remains for everyone. The WHO's 2030 target offers a narrow corridor toward correction, but only if governments choose, urgently, to walk through it.
The world is misusing antibiotics, and a new study in The Lancet Public Health has mapped the damage with unusual precision. Researchers from the University of London built a country-by-country framework calculating how much of each antibiotic class every nation should be using, based on disease burden, poverty, and resistance patterns. Their baseline: roughly 43 billion antibiotic courses were needed globally in 2019, with about 77 percent meant to come from basic 'access' drugs like amoxicillin, and the remainder carefully divided between stronger 'watch' and last-resort 'reserve' categories.
When actual prescribing data from 67 countries was measured against those benchmarks, the results were alarming. Nearly three-quarters of nations were consuming more antibiotics than their disease profiles warranted. More troubling still, 99 percent were dramatically overprescribing 'watch' antibiotics — the heavy-duty drugs designed only for infections that simpler treatments cannot resolve. Overuse of these medicines accelerates the emergence of bacteria resistant to multiple drugs simultaneously.
India offers a vivid example. Its safe consumption range was estimated at 9.9 to 14.7 defined daily doses per 1,000 people per day; actual use reached 18.3, with watch-class drugs accounting for much of the excess. The pattern is global. Meanwhile, a cruel inversion shapes the inequality beneath the data: low and middle-income countries, which bear the greatest burden of drug-resistant infection, need proportionally more specialized antibiotics — yet high-income nations consume them most. More than half the countries studied lacked sufficient reserve antibiotics for patients with genuinely resistant, life-threatening infections, and 60 percent were still prescribing drugs the WHO has deemed obsolete.
Researchers are urging a dual response: curb unnecessary prescribing where it is rampant, while simultaneously improving access for those who genuinely need stronger drugs. The UN General Assembly endorsed the WHO's antibiotic classification framework in 2024, but endorsement without enforcement changes little. The 2030 target remains within reach — just barely, and only if countries act now.
The world is using antibiotics wrong, and nearly everywhere at once. A new study published in The Lancet Public Health has mapped out what sensible antibiotic consumption should look like for every country on Earth—and found that 99 percent of nations are overdosing on the drugs that pose the greatest risk of breeding resistant superbugs.
The problem centers on a category called 'watch' antibiotics. These are the heavy artillery of the antibiotic arsenal: stronger drugs meant to be deployed only when simpler treatments fail. When overused, they accelerate the evolution of bacteria that can shrug off multiple medicines at once. Researchers from the University of London and collaborating institutions developed a framework to calculate how much of each antibiotic class a country should actually be using based on its disease burden, poverty levels, and existing resistance patterns. The math was straightforward enough: globally, about 43 billion antibiotic courses were needed in 2019 to treat all bacterial infections—roughly one course per person per year. Of those, roughly 77 percent should have come from 'access' antibiotics, the basic drugs like amoxicillin used for common infections. The remaining share should split between 'watch' and 'reserve' categories, with reserve drugs held in strict reserve for life-threatening infections that nothing else can touch.
When the researchers compared their calculations to actual prescribing data from 67 countries, the gap was staggering. Nearly three-quarters of those nations were using more total antibiotics than their disease profiles justified. But the real alarm came from the 'watch' category: 99 percent of countries with available data were prescribing these drugs far more than they should. The World Health Organization had set a target that by 2030, at least 70 percent of global antibiotic use should come from the access group. The study suggests that target is achievable—but only if countries dramatically change course.
India illustrates the imbalance. The country should have been using between 9.9 and 14.7 defined daily doses per 1,000 people per day. Instead, it was using 18.3. More than half of that excess came from 'watch' antibiotics, while access drugs made up only a quarter of actual use. The same pattern repeats across the globe: countries are reaching for the stronger drugs when they should be reaching for the weaker ones.
Underlying this misuse is a cruel irony of global health inequality. Low and middle-income countries, which carry the heaviest burden of infectious disease and drug resistance, actually need proportionally more of the specialized 'watch' and 'reserve' antibiotics to treat their sicker populations. Yet high-income nations are the ones consuming these drugs most heavily. Meanwhile, more than half the countries studied were not using enough reserve antibiotics, meaning patients with truly resistant infections—the ones that genuinely need these last-resort drugs—were going without them. Sixty percent of countries were still prescribing antibiotics that the WHO has said should no longer be used at all.
The researchers are calling for urgent national policies that do two things simultaneously: reduce unnecessary prescribing in places where it's rampant, and improve access for patients who genuinely need specialized drugs. It is a delicate balance, and the clock is ticking. The UN General Assembly agreed in 2024 that the WHO's Access, Watch, Reserve system should guide global antibiotic surveillance. But without country-level targets and enforcement mechanisms, the overuse will continue—and with it, the steady rise of bacteria that medicine can no longer kill.
Notable Quotes
Of 67 countries, territories and areas with observed antibiotic use data, 72 percent used higher total antibiotic volumes than expected and 99 percent used more 'watch' antibiotics than expected— Study authors in The Lancet Public Health
Low and middle-income countries, which face heavier burdens of infectious disease and drug resistance, need proportionally more specialized antibiotics, yet higher-income countries are currently using these types the most— Study researchers
Want the full story?
Read the original at The Shillong Times ↗
Health & Medicine